Cargando…
Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia
OBJECTIVE: Primary myelofibrosis is a rare type of myeloproliferative neoplasm with an annual incidence rate of 0.47 per 100,000. A retrospective, observational study was conducted to determine the disease evolution and costs of treatment for myelofibrosis (MF) patients managed in 4 Ministry of Heal...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334073/ https://www.ncbi.nlm.nih.gov/pubmed/36974524 http://dx.doi.org/10.31557/APJCP.2023.24.3.733 |
_version_ | 1785070788854939648 |
---|---|
author | Tang, Andy Sing Ong Leong, Tze Shin Ong, Joyce Hong Ling Goh, Adrian Chew, Lee Ping |
author_facet | Tang, Andy Sing Ong Leong, Tze Shin Ong, Joyce Hong Ling Goh, Adrian Chew, Lee Ping |
author_sort | Tang, Andy Sing Ong |
collection | PubMed |
description | OBJECTIVE: Primary myelofibrosis is a rare type of myeloproliferative neoplasm with an annual incidence rate of 0.47 per 100,000. A retrospective, observational study was conducted to determine the disease evolution and costs of treatment for myelofibrosis (MF) patients managed in 4 Ministry of Health (MOH) hospitals in Sarawak, Malaysia. METHODS: The estimation of treatment cost was a planned analysis of the Real World Evidence (RWE) study which included retrospective chart review of adult MF patients treated in Sarawak General, Sibu, Bintulu and Miri Hospitals. The study was approved by Sarawak General Hospital HRRC and MREC. The current study was conducted to estimate the cost of out-patient visits, hospitalisation, transfusion and medication from the perspective of MOH. Out-patient visits and hospitalisation costs were calculated using current unit costs for full fee-paying charges of MOH hospitals. Transfusion costs were estimated for packed cell and platelet transfusions. Medication costs were calculated using drug prices from IQVIA database for MOH hospital sub-sector in 2021. Unit costs were standardised to index year of 2021. RESULT: Data from 63 patients was available for analysis. Mean annual health resource utilisation (HRU) was 6.13 clinic visits, 9.47 days of hospitalisation and 1.61 transfusions per patient per year. Mean HRU cost was RM23,320 (USD5,217) per patient per year, comprised of RM19,122 (USD4,278) in drug costs, RM3,030 (USD678) for hospitalisation, RM799 (USD178) for transfusions and RM368 (USD82) for outpatient cost. CONCLUSION: The present analysis suggests that medication and hospitalisation were the main drivers of costs for MF treatment in Sarawak MOH hospitals. This study provides the first RWE estimate of the cost of MF in Malaysia and may provide insight into unmet clinical needs and a guide for further health economic research into the treatment of MF. |
format | Online Article Text |
id | pubmed-10334073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-103340732023-07-12 Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia Tang, Andy Sing Ong Leong, Tze Shin Ong, Joyce Hong Ling Goh, Adrian Chew, Lee Ping Asian Pac J Cancer Prev Short Communication OBJECTIVE: Primary myelofibrosis is a rare type of myeloproliferative neoplasm with an annual incidence rate of 0.47 per 100,000. A retrospective, observational study was conducted to determine the disease evolution and costs of treatment for myelofibrosis (MF) patients managed in 4 Ministry of Health (MOH) hospitals in Sarawak, Malaysia. METHODS: The estimation of treatment cost was a planned analysis of the Real World Evidence (RWE) study which included retrospective chart review of adult MF patients treated in Sarawak General, Sibu, Bintulu and Miri Hospitals. The study was approved by Sarawak General Hospital HRRC and MREC. The current study was conducted to estimate the cost of out-patient visits, hospitalisation, transfusion and medication from the perspective of MOH. Out-patient visits and hospitalisation costs were calculated using current unit costs for full fee-paying charges of MOH hospitals. Transfusion costs were estimated for packed cell and platelet transfusions. Medication costs were calculated using drug prices from IQVIA database for MOH hospital sub-sector in 2021. Unit costs were standardised to index year of 2021. RESULT: Data from 63 patients was available for analysis. Mean annual health resource utilisation (HRU) was 6.13 clinic visits, 9.47 days of hospitalisation and 1.61 transfusions per patient per year. Mean HRU cost was RM23,320 (USD5,217) per patient per year, comprised of RM19,122 (USD4,278) in drug costs, RM3,030 (USD678) for hospitalisation, RM799 (USD178) for transfusions and RM368 (USD82) for outpatient cost. CONCLUSION: The present analysis suggests that medication and hospitalisation were the main drivers of costs for MF treatment in Sarawak MOH hospitals. This study provides the first RWE estimate of the cost of MF in Malaysia and may provide insight into unmet clinical needs and a guide for further health economic research into the treatment of MF. West Asia Organization for Cancer Prevention 2023 /pmc/articles/PMC10334073/ /pubmed/36974524 http://dx.doi.org/10.31557/APJCP.2023.24.3.733 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Short Communication Tang, Andy Sing Ong Leong, Tze Shin Ong, Joyce Hong Ling Goh, Adrian Chew, Lee Ping Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia |
title | Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia |
title_full | Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia |
title_fullStr | Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia |
title_full_unstemmed | Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia |
title_short | Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia |
title_sort | cost of treatment for myelofibrosis patients in ministry of health hospitals in sarawak, malaysia |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334073/ https://www.ncbi.nlm.nih.gov/pubmed/36974524 http://dx.doi.org/10.31557/APJCP.2023.24.3.733 |
work_keys_str_mv | AT tangandysingong costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia AT leongtzeshin costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia AT ongjoycehongling costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia AT gohadrian costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia AT chewleeping costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia |